Neuromodulation Pioneer, IveaCare, Assembles Elite Team for Groundbreaking R&D Phase
Operating below the radar, IveaCare is rapidly building an interdisciplinary team combining deep expertise from leading clinical research, neuroscience, and eng…
iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors IveaCare Secures
MINNEAPOLIS, April 22, 2024 — iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing.